386 related articles for article (PubMed ID: 35774424)
1. The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.
Li F; Chen Y; Wu J; Li C; Chen S; Zhu Z; Qin W; Liu M; Hu B; Liu S; Zhong W
Chronic Dis Transl Med; 2022 Jun; 8(2):100-111. PubMed ID: 35774424
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
Chiu LC; Lin SM; Lo YL; Kuo SC; Yang CT; Hsu PC
Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34201650
[TBL] [Abstract][Full Text] [Related]
6. Moving Immunotherapy Into Early-Stage Lung Cancer.
Linehan A; Forde PM
Cancer J; 2020; 26(6):543-547. PubMed ID: 33298726
[TBL] [Abstract][Full Text] [Related]
7. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.
Riano I; Abuali I; Sharma A; Durant J; Dragnev KH
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259381
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
9. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
11. Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers.
Wu X; Chau YF; Bai H; Zhuang X; Wang J; Duan J
Front Oncol; 2022; 12():1099304. PubMed ID: 36761426
[TBL] [Abstract][Full Text] [Related]
12. Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer.
Guo H; Li W; Qian L; Cui J
Chin J Cancer Res; 2021 Apr; 33(2):203-215. PubMed ID: 34158740
[TBL] [Abstract][Full Text] [Related]
13. [Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer].
Shu C; Zhu D; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):130-136. PubMed ID: 35224967
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone.
Tang WF; Ye HY; Tang X; Su JW; Xu KM; Zhong WZ; Liang Y
Front Oncol; 2023; 13():1063183. PubMed ID: 36776323
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
16. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review.
Gatteschi L; Iannopollo M; Gonfiotti A
Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685407
[TBL] [Abstract][Full Text] [Related]
18. An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy.
Verma S; Breadner D; Mittal A; Palma DA; Nayak R; Raphael J; Vincent M
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610980
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives.
Lim SM; Hong MH; Kim HR
Immune Netw; 2020 Feb; 20(1):e10. PubMed ID: 32158598
[TBL] [Abstract][Full Text] [Related]
20. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
Huang Z; Su W; Lu T; Wang Y; Dong Y; Qin Y; Liu D; Sun L; Jiao W
Front Pharmacol; 2020; 11():578091. PubMed ID: 33117170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
